Cheaper drug could maintain leukemia control after stronger treatment
NCT ID NCT01316250
Summary
This study tested a treatment strategy for newly diagnosed chronic myeloid leukemia. Researchers wanted to see if patients who responded well to an initial strong drug (nilotinib) could switch to a cheaper, easier-to-use drug (imatinib) to maintain that response long-term. The goal was to control the leukemia while reducing treatment costs and side effects for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOGENOUS LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
American University of Beirut Medical Center
Beirut, Lebanon
Conditions
Explore the condition pages connected to this study.